Hcular heterogeneityostate cancer: Canmutation unravelrigenesis?

Molecular Medicine Today

Volumn 3, Issue 11, 1997, Pages 476-482

  Zheng, Jianping ^a   Miller, Gary J ^a   Roy Burman, Pradip ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; DISEASE COURSE; GENETIC HETEROGENEITY; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE TUMOR; SINGLE STRAND CONFORMATION POLYMORPHISM; STEM CELL;

DISEASE PROGRESSION; GENETIC HETEROGENEITY; HUMANS; MALE; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031266344     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1357-4310(97)01126-x     Document Type: Article

References (33)

1. Giftes, R.F. (1991) Carcinoma of prostate, New Engl. J. Med. 324, 236-245
2. Sandberg, A.A. (1992) Chromosomal abnormalities and related events in prostate cancer, Hum. Pathol. 23,368-380
3. Miller, G.J. and Cygan, J.M. (1994) Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration, J. Urol. 151,1587-1592
4. Karp, J.E. and Broder, S. (1995) Molecular foundations of cancer: new targets for intervention, Nat. Med. 1,309-320
5. Sidransky, D. etal. (1992) Clonal origin of bladder cancer, New Engl. J. Med. 326, 737-740
6. Noguchi, S. etal. (1994) Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis, Cancer 74, 872-877
7. Tsao, S.W. et al. (1993) Molecular genetic evidence for a unifocal origin of human serous ovarian carcinomas, Gynecol. Oncol. 48,5-10
8. Nowell, P.C. (1976) Theclonal evolution of tumor cell populations, Science 194,23-28
9. Ruijter, ET. et al. (1996) Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications, J. Pathol. 180,295-299
10. Karp, J.E. ef al. (1996) Prostate cancer prevention: investigational approaches and opportunities, Cancer Res. 56, 5547-5556
11. Warzynski, M.J. etal. (1995) DNA heterogeneity determined by flow cytometry in prostatic adenocarcinoma - necessitating multiple site analysis, Prostate 27,329-335
12. Mirchandani, D. et al. (1995) Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer, Am. J. Pathol. 147, 92-101
13. Konishi, N. et al. (1995) Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma, Am. J. Pathol. 147,1112-1122
14. Gumerlock, P.M. etal. (1997) Abnormalities in primary prostate cancer: single-strand conformational polymorphism analysis of complementary DNA in comparison with genomic DNA, J. Natl. Cancer Inst. 89, 66-71
15. Jenkins, R.B. et al. (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostate carcinoma by fluorescence in situ hybridization, Cancer Res. 57, 524-531
16. Konishi, N. etal. (1997) Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas, Am. J. Pathol. 150, 305-314
17. Lane, DP. (1992) p53, guardian of the genome, Nature 358,15-16
18. Kastan, M.B., Canman, C.E. and Leonard, C.J. (1995) P53, cell cycle control and apoptosis: implications for cancer, Cancer Metastasis Rev. 14, 3-15
19. Greenblatt, M.S., Bennett, W.P., Hollstein, M. and Harris, C.C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res. 54, 4855-4878
20. Kastan, M.B. ef al. (1992) A mammalian checkpoint pathway utilizing p53 and gadd45 is defective in ataxia-telangiectasia, Cell 71,587-597
21. Lee, J.M. and Bernstein, A. (1995) Apoptosis, cancer and the p53 tumour suppressor gene, Cancer Metastasis Rev. 14,149-161
22. Bookstein, R. ef al. (1993) p53 is mutated in a subset of advanced-stage prostate cancers, Cancer Res. 53,3369-3373
23. Shibata, D. ef al. (1992) Specific genetic analysis of microscopic tissue after selective ultraviolet radiation fractionation and the polymerase chain reaction, Am. J. Pathol. 141,539-543
24. Kamb, A. ef al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types, Science 264,436-440
25. Effert, P.J., Neubauer, A., Walther, P.J. and Liu, E.T. (1992) Alterations of the TP53 gene as associated with the progression of a human prostate carcinoma, J. Urol. 147,789-793
26. Chi, S-G. et al. (1994) p53 in prostate cancer: frequent expressed transition mutations, J. Natl. Cancer Inst. 86, 926-933
27. Navone, N.M. et al. (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma, J. Natl. Cancer Inst. 85,1657-1669
28. Salem, C.E. et al. (1997) p53 protein and gene alteration in pathologic stage C prostate carcinoma, J. Urol. (in press)
29. Dittmer, S. et al. (1993) Gain of function mutations in p53, Nat. Genet. 4,42-46
30. Harvey, M. eraJ. (1995) A mutant p53 transgene accelerates tumor development in heterozygotes but not nullizygous p53-deficient mice, Nat. Genet. 9,305-311
31. Issacs, J.T. (1997) Molecular markers for prostate cancer metastasis: developing diagnostic methods for predicting the aggressiveness of prostate cancer, Am. J. Pathol. 150, 1511-1521
32. Graeber, T.G. etal. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature 379, 88-91
33. Kinzler, K.W. and Vogelstein, B. (1996) Life (and death) in a malignant tumour, Nature 379,19-20